➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Express Scripts
McKesson
Colorcon
Baxter

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Patent: 8,143,237

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,143,237
Title:Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): ##STR00001## wherein the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.6, and R.sup.7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing\'s sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
Inventor(s): Gokaraju; Ganga Raju (Vijayawada, IN), Kasina; Sudhakar (Mercer Island, WA), Gokaraju; Rama Raju (Vijayawada, IN), Gokaraju; Venkata Kanaka Ranga Raju (Vijayawada, IN), Somepalli; Venkateswarlu (Vijayawada, IN), Golakoti; Trimurtulu (Vijayawada, IN), Bhupathiraju; Kiran (Vijayawada, IN), Krishanu; Sengupta (Vijayawada, IN), Alluri; Venkata Krishna Raju (Vijayawada, IN)
Assignee: Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN)
Application Number:12/767,647
Patent Claims:see list of patent claims

Details for Patent 8,143,237

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2029-04-27 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2029-04-27 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2029-04-27 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2029-04-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKesson
Mallinckrodt
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.